BITs, RTAs and Non-Equity Modes (NEMs) and their impact on Transfer of Technology WTO Working Group on Trade and Transfer of Technology Geneva,
Download ReportTranscript BITs, RTAs and Non-Equity Modes (NEMs) and their impact on Transfer of Technology WTO Working Group on Trade and Transfer of Technology Geneva,
BITs, RTAs and Non-Equity Modes (NEMs) and their impact on Transfer of Technology WTO Working Group on Trade and Transfer of Technology Geneva, 8 November 2012 Christoph Spennemann Legal Expert, IP Unit UNCTAD Overview • • • • • • The notion of NEMs of investment The rationale behind NEMs Determinants of NEMs – the role of BITs & RTAs NEM and technology transfer Policy recommendations Sources: – UNCTAD « World Investment Report 2011: Non-Equity Modes of International Production and Development » – UNCTAD-WHO-ICTSD: « Local Production of Pharmaceuticals and Related Technology Transfer in Developing Countries », 2011 NEMs of investment • Contractual relationship between TNCs and partner firms • Control over host-country business by means other than equity holdings (as opposed to FDI) • NEM types that are relevant for technology – Licensing (intellectual property rights/IPRs) – Franchising – Contract manufacturing/services outsourcing • Main areas: e.g. pharmaceuticals, automotive components, IT services, electronics, etc. Non-equity modalities: A middle ground between FDI and trade WIR2011 aims to bridge the gap in policy analysis Figure IV.1, WIR11, p. 125. 7 Estimated worldwide sales by type of NEM, 2010 (Trillions of dollars) Figure IV.3, WIR11, p. 132. 9 International licensing, which is not confined to any one industry, has grown significantly in the past decades (NEM-related licensing sales in billions of dollars) 6 NEM advantages for TNCs… • Low upfront capital expenditure needed • Results in reduced risk exposure • Greater flexibility in adapting to changes in business cycle and demand • Externalization of non-core activities – Example: outsourcing of R&D and/or clinical trials in pharmaceutical value chain to generic producers in Argentina, India … and local partners • Sharing of benefits • Better access to technology, skills, etc. • Technological & productive capacity building • Core pre-condition: absorption capacity ! Locational determinants • Relevant for both FDI and NEMs (examples) – Economic, political, social stability – Infrastructure • More relevant for FDI decisions – Bilateral & international investment protection (BITs & IIAs) – Investment promotion & incentives • More relevant for NEM approaches – Stable commercial & contract law – Intellectual property protection (TRIPS, FTAs, RTAs) – Upgrading of technological capacities of local partners NEMs & technology transfer (TOT) • NEMs can diffuse technology & skills to local partners – NEMs are part of TNCs’ global value chains – TOT to some extent desired by TNCs • Example: pharmaceutical industry in Bangladesh acquired initial capacity through licensing agreements with TNCs • Extent of technology uptake depends on local absorptive capacities – Example: TNCs left Colombia before skills were fully transferred to local pharmaceutical industry – Not all NEMs involve programs for training – Importance of domestic skills building Example: ELEA/Argentina (producer of pharmaceuticals, biotech vaccines) • Three sources of technology: – (1) In-house R&D – (2) Alliances with universities & research centers in Argentina & Cuba – (3) Licensing agreement with US firms Warner Lambert/Pfizer • Know-how for product formulation, not new product development • Blockbuster Lipitor ® only for distribution • Transfer of plant & personnel • Imposed standards for GMP & drug quality NEMs & TOT – the role of IPRs • IP protection may encourage investor to opt for NEMs (e.g. licensing to local partner) rather than FDI – Role of TRIPS, FTAs, RTAs for investor – But only one element in investment consideration (example Colombia/pharma) • IPRs complicate use of reverse engineering and domestic capacity building through informal means of TOT – What is the importance of formal or informal means of TOT in a country? – Balanced implementation of TRIPS in developing countries: flexibilities (patentability standards, research exception, competition law & policy, etc) – FTAs, RTAs and « TRIPS-Plus » WIR 2011 recommendations: how to maximize development benefits from NEMs • Embedding NEM policies in overall development strategies • Building domestic productive capacity • Facilitating and promoting NEMs • Addressing negative effects (e.g. local partner remains locked in basic technology)